Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.50 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479830 | 1.00 | CALCRL (0.50) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6486199 | 0.95 | CALCRL (0.48) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6490055 | 0.91 | CALCRL (0.42) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6490050 | 0.91 | CALCRL (0.42) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6478781 | 0.90 | CALCRL (0.51) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6478784 | 0.90 | CALCRL (0.51) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6490766 | 0.89 | CALCRL (0.52) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6490764 | 0.89 | CALCRL (0.52) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6478163 | 0.89 | CALCRL (0.45) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL6478165 | 0.89 | CALCRL (0.45) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | claimed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | CALCA, CALCRL, P2RY1 | CALCRL 2/4885RAMP1 51/4885CYP3A4 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.